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Introduction
Stress urinary incontinence (SUI) and pelvic organ prolapse 
(POP) are common conditions affecting women worldwide 
and are associated with significant morbidity and impact on 
quality of life. It is estimated that 10% of parous women in the 
UK will go on to require surgical intervention for pelvic floor 
dysfunction1.
Historically, the surgical options for SUI and POP relied on 
directly repairing the patient’s own native tissues by using 
sutures2 or repositioning strips of the patient’s fascia to provide 
support3. The Burch colposuspension uses a retropubic approach 
to resuspend the bladder neck back to the correct anatomical 
location by using sutures. For POP, surgeons used sutures 
to strengthen the walls of the vagina or to return the pelvic 
organs to their natural positions. The options for SUI included 
the use of an autologous fascial sling, which was popular-
ised by McGuire in the 1970s2. Here, a strip of rectus fascia or 
fascia lata is used to provide support to the urethra.
The prevalence of SUI and POP typically increases with age, 
and the peak incidence is in post-menopausal, multiparous 
women. Several other factors (related to both lifestyle and genet-
ics), including obesity3 and smoking and connective tissue 
disorders4, may contribute to pelvic floor instability. As such, the 
recurrence and reoperation rates for prolapse with native tissue 
repair alone were high (failure rate of 17 to 20% at 10 years5) 
as the patient’s tissues often are not of sufficient quality or 
strength to be repaired. To circumvent this issue, mesh began to 
be used to strengthen the repair. The most common material 
used in these surgeries has been synthetic, polypropylene (PPL) 
mesh, which is used to support either the urethra (for SUI) or 
the pelvic organs (for POP). In the case of SUI, this is via the 
placement of a mid-urethral sling/tape to provide support to the 
urethra. For POP repair, the repair technique differs depending 
on the type of prolapse. Broadly speaking, two surgical approaches 
can be used: abdominal and transvaginal. Sacrocolpopexy and 
sacrohysteropexy use the abdominal placement of mesh from 
the sacrum to the vagina or uterus to restore the organs to 
their natural positions6. Both operations can be performed 
through open surgery but are more commonly laparoscopic. 
Colporrhaphy is an open, transvaginal repair using absorbable 
sutures to plicate the tissues of the anterior or posterior walls (or 
both) of the vagina and mesh to reinforce the repair. The goals 
are to provide extra support to the pelvic floor for the overly-
ing organs and prevent further prolapse of either the bladder 
(cystocele) or rectum (rectocele) into the vagina7.
The use of mesh in pelvic floor repair was standard practice for 
many years prior to the release of a public health notification by 
the US Food and Drug Administration (FDA) in 20088. This 
highlighted that they had received an alarmingly high number 
of reports (more than 1000) concerning complications asso-
ciated with transvaginal mesh placement in SUI and POP in 
the preceding 3 years. Subsequent releases confirmed that 
these initial reports were not an anomaly and that many patients 
worldwide were experiencing serious adverse events as a result 
of mesh implantation9. These complications included recur-
rence of SUI/POP, pain, infection and mesh erosion which have 
left many women unable to function in their everyday lives. This 
has led to huge lawsuits against both manufacturers and indi-
vidual surgeons; as a result, many device manufacturers have 
dropped pelvic mesh products entirely. Although it is difficult 
to quantify the exact total cost of litigation due to out-of-court 
settlements, Endo International Plc (a global pharmaceutical 
company that purchased American Medical Systems in 201110, 
thereby inheriting the subsequent litigation associated with their 
mesh products) has set aside $2.6 billion in reserves to deal 
with mesh lawsuits11. This is now acknowledged as an impor-
tant issue in healthcare. Future developments of new products 
in this market quite correctly will require intense regulatory 
scrutiny.
Biomaterials
The synthetic, biological, biodegradable or non-biodegradable 
options currently in use or under study for use within the pelvic 
floor are considered below. A number of polymers have been 
developed and have been used in this context. Unfortunately, to 
many, the word polymer has become synonymous with the word 
plastic. This is an oversimplification of a broad range of materi-
als. A polymer is a substance composed of macromolecules12. 
Plastics are a group of synthetic polymers, often with other 
chemicals and colouring agents added. All plastics are polymers 
certainly, but not all polymers are plastics. It is important to 
note that many different polymers exist in nature (for example, 
cellulose and even DNA). Many different polymers have 
been used to investigate pelvic floor repair. These include but 
are not limited to polylactic acid (PLA)13–20, polylactic-co- 
glycolic acid (PLGA)21–24, polyamide25,26, purified collagen gel 
(PPC)27, polyurethane (PU)16,28, polyvinylidene fluoride (PVDF)15, 
polycaprolactone (PCL)22,29 and PPL30,31.
PPL is a widely used polymer and is used in products rang-
ing from packaging, clothing, car bumpers to toys as well as 
a multitude of medical components32. Indeed, owing to its 
chemical stability and non-biodegradable nature, it is the most 
common material used in synthetic mesh production. PPL meshes 
have a monofilament structure, are macroporous and have a large 
enough pore size to allow host cell infiltration. The rationale 
behind this is that host cell infiltration allows better tissue inte-
gration and therefore improved healing and union. PPL meshes 
were first used for abdominal wall hernia repair, and similar 
issues of pain and shrinkage were reported during their intro-
duction. In studies in dogs, Klinge et al.33 identified a foreign 
body reaction and persistent inflammation surrounding the 
PPL meshes, and there was extensive fibrosis and 30 to 50% 
shrinkage in the first month after implantation34.
In response to the complications associated with PPL mesh 
in the pelvic floor, manufacturers have produced both “light 
weight” versions and other modified PPL meshes to attempt 
to reduce the excessive fibrosis and inflammation which are 
likely to contribute to exposure in the vagina or erosion through 
the pelvic organs. Feola et al.31 compared the host response to 
several commercially available PPL meshes in sheep, includ-
ing meshes with added collagen coatings. Their study found that 
the addition of collagen did not improve graft-related compli-
cation rates. Hachim et al.35 modified commercially available 
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PPL meshes with an interleukin-4 (IL-4)-releasing coating. 
They found that this coating was able to shift host macrophages 
towards an M2 macrophage response, thus mitigating the foreign 
body response usually seen with PPL.
PLA is a commonly used polymer in tissue engineering. PLA 
medical devices are already used in surgery, particularly within 
orthopaedics. PLA is produced by the bacterial fermentation 
of carbohydrates; typically, this is corn starch on an industrial 
scale36. It is renewable and biodegradable and degrades by hydrol-
ysis into lactic acid, which is readily metabolised within the 
body. De Tayrac et al.13 demonstrated that a PLA mesh retained 
acceptable strength in vitro for 8 months and demonstrated 
good biocompatibility in vivo after 90 days of implantation 
in an incisional hernia rat model. PLA is extremely biocom-
patible, but given its biodegradability, there are concerns that 
PLA may not provide the long-term structural support required 
for a successful pelvic floor repair.
Electrospinning is a technique used to manufacture polymer 
scaffolds. It works by using electricity to produce fibres from 
polymer solutions, weaving them into nanofibrous mats37. PLA 
can be used as a drug delivery system through the method of 
emulsion electrospinning. This allows the incorporation of 
hydrophilic substances into PLA fibres. Mangir et al.17 successfully 
produced PLA scaffolds that released two derivatives of ascor-
bic acid. Fibroblasts then were seeded onto each scaffold 
and were found to produce more collagen in the presence of 
ascorbic acid compared with cells seeded onto control scaf-
folds. In further work, Mangir et al.14 developed PLA scaffolds 
that released controlled doses of oestradiol. These scaffolds were 
found to increase the extracellular matrix production of seeded adi-
pose-derived mesenchymal stem cells (ADMSCs) and stimulate 
angiogenesis. Electrospun PU scaffolds have since been aug-
mented with the addition of oestradiol, which has been shown to 
remarkably promote angiogenesis and improve the mechanical 
properties of the scaffold28.
Biological grafts have also been used in the pelvic floor, and 
several commercial xenografts, including porcine small intestinal 
mucosa, bovine dermis or pericardium, have been produced. These 
tissues undergo extreme processing and sterilisation measures 
to reduce the risk of both rejection and infection but this does 
result in rapid degradation. The materials are non-porous and 
do not allow continuous host cell integration, leading to poor 
tissue union. As such, similar to PPL, they often induce a fibrotic 
reaction. Systematic reviews have not found an advantage 
to using xenografts over native tissue repair or light-weight 
synthetic mesh38. Cadaveric dermal allografts have also been used 
previously39 but these are costly and entail a small but theoreti-
cal risk of blood-borne virus transmission. Seitz et al. compared 
patient outcomes for those undergoing hysteropexy augmented 
with PPL mesh versus hysteropexy with cadaveric dermal 
allograft39. This study found that the PPL group had a lower 
recurrence rate compared with the allograft group (18% recur-
rence rate with mesh and 29% recurrence rate with allograft), 
but there was a mesh exposure rate of 5.75% in the former 
group39.
MatriStem™ is a commercially available extracellular matrix 
bio-scaffold derived from the porcine urinary bladder and is 
used topically for wound management40. This was used by Liang 
et al.41 in monkeys to repair transected uterosacral ligaments 
and paravaginal attachments to the pelvic side wall. Matristem™ 
was used to repair the transected ligaments through either a 
transvaginal or transabdominal incision. These animals were then 
compared to others who had the same operation as the Matris-
tem™ implanted animals (laparotomy +/- vaginal incision) 
but did not undergo “disruption of level I and II support or the 
application of the bioscaffold”. The authors found that, in 
comparison with these ‘sham-operated’ controls, there were new 
tissue bands that had replaced the implanted material. This does 
raise the possibility that this material could be used for the regen-
eration of damaged supportive tissues within the pelvic floor in 
women with POP but clearly more studies need to be performed 
for this indication.
The choice of material for use in the pelvic floor is vitally impor-
tant as it must be able to withstand stress and strain but should 
also be flexible and have inherent elasticity. This is important 
to prevent the material from deforming and losing its designed 
structure and from being so stiff as to erode through a patient’s 
own tissues or even into the viscera. The pelvic floor is an area 
of the body that undergoes significant movement and morpho-
logical changes throughout a woman’s lifetime and any implanted 
material would need to be able to cope with the stressors 
associated with such a dynamic environment.
Tissue engineering
Tissue engineering is a branch of regenerative medicine and 
aims to create functional tissues through the combination of 
scaffolds, cells and other compounds. The aim is to repair or 
replace damaged native tissue.
The emergence of severe complications associated with PPL 
mesh has left surgeons with very limited options to treat POP, 
particularly when recurrent. There is now an unmet need for new 
treatments to fill the void left by PPL mesh and repair the weak-
ened pelvic floor. Thus, there is a renewed focus on locating 
suitable replacements for PPL mesh to provide mechanical 
support but avoid the associated complications of pain and tissue 
erosion. This has stimulated researchers to look for alternative 
materials and there are a range of natural, synthetic, biodegradable 
or non-biodegradable options from which to choose.
The addition of cells to a material has been shown to improve 
the host response to that biomaterial in comparison with using 
the same material without cells added19. Several different cell 
lines, including fibroblasts, smooth muscle cells and adult stem 
cells, have been proposed to use within the pelvic floor. Stem 
cells can be isolated from a variety of locations, including bone, 
blood, fat, skin, synovial fluid42 and endometrium43,44. Mesen-
chymal stem cells (MSCs) are multipotent45, meaning that they 
can differentiate into several tissue types, including fat, bone, 
cartilage, tendon and smooth muscle46. MSCs have different 
paracrine effects which aid in wound healing47. They can secrete 
immunomodulatory factors to encourage local tissue growth, 
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control the inflammatory response, recruit neighbouring cells for 
tissue repair48 and promote angiogenesis42.
Ulrich et al.49 demonstrated that endometrial MSCs seeded onto 
gelatin-coated polyamide mesh had an anti-inflammatory effect 
and promoted neovascularisation in a rat model. This study 
demonstrated that the meshes that had been seeded with cells 
also had significantly improved biomechanical properties with 
decreased stiffness and minimal fibrosis. Similarly, the addition 
of ADMSCs has been noted to improve the performance of 
different biomaterials in many other studies19,21,50.
Within the pelvic floor, Wang et al.51 have described a method 
of using pluripotent stem cell derivatives for the regenera-
tion of the internal urethral sphincter. The pluripotent stem 
cells were induced into differentiation into a pure population of 
smooth muscle precursor cells. With a rat model, these precursor 
cells were injected peri-urethrally 3 weeks after inducing an 
acute sphincter injury. The study data demonstrated improvements 
in leak point pressures in the smooth muscle precursor cell–
injected rats, consistent with restoration of urethral sphincter 
function. This work showed the potential for smooth muscle 
precursor cells, derived from pluripotent stem cells, to restore 
meaningful function to the internal urethral sphincter in acute 
injury. However, further studies have highlighted the limitations 
of injected cellular therapies for urinary sphincter deficiency 
with reduced efficacy seen when used to treat chronic 
pathology52.
There is no question that cells can be implanted and proliferate 
in the presence of a suitable blood supply; the question is, will 
they go on to produce functional tissue at the target area of 
implantation? In the case of SUI, there may be denervation of 
the urinary sphincters and any resulting tissues derived from 
implanted cells are unlikely to become innervated. Equally, if 
the sphincters remain innervated, any subsequent tissues may 
not contract in a functional, physiological manner in synergy with 
bladder contraction to restore continence. Cell-based therapies 
have shown merit; however, at present, they are limited practically 
in their feasibility to translate to a workable product for use in 
an operating theatre. Using cells that have been manipulated 
in a laboratory and combining them with a material turn the 
material into an “advanced therapy medicinal product”53, and 
much greater time and resources are required to produce them 
and there are greater regulatory hurdles to satisfy for market 
approval. With increasing research evidence demonstrating the 
value of cell-based therapies, perhaps the greater challenge is to 
overcome these practical limitations.
Animal models
Increasingly, alternative methods of quantifying the biomechan-
ics of the pelvic floor, including computational methods and 
animal models, have been used54. Recent advances have helped 
us to better quantify the biomechanical properties of the female 
pelvic floor and in turn should lead to products with better in 
vivo predictability in the future. Lei et al.55 characterised the 
biomechanical properties of vaginal tissue in women with POP 
both pre- and post-menopause. The authors found a significant 
difference in biomechanical properties between the POP and 
control groups in both pre- and post-menopausal women, 
suggesting that a degeneration of biomechanical properties of 
vaginal tissue is likely to be a precursor for the development of 
POP. Röhrnbauer et al.56 described a new method for in vivo intra-
vaginal measurement of the mechanical properties of the anterior 
vaginal wall. Using a novel aspiration device, they studied the 
degree of tissue displacement seen in women both with and 
without POP. The authors found that patients who had under-
gone an anterior colporrhaphy had statistically significantly 
reduced tissue displacement in comparison with pre-operative 
patients. A modified speculum to enable real-time measurement 
of vaginal biomechanics in an ovine model was described by 
Parkinson et al.57. As these types of devices are trialled and 
developed, we may be able to reduce our reliance on animal 
models in the future.
Currently, animal models are an integral component of pre-
clinical testing of new biomaterials. Several studies have looked 
at biomaterials implanted into the abdominal walls of rabbits. 
Roman et al. implanted PLA scaffolds into the abdominal walls 
of rabbits15. PLA demonstrated better integration with host tissues 
in comparison with PVDF and PPL mesh. The commercial 
PVDF and PPL meshes both produced a chronic inflammatory 
response in the surrounding tissues. Conversely, the PLA and PU 
scaffolds showed evidence of constructive remodelling, showing 
an M2 macrophage response with angiogenesis15. Clearly, the 
abdominal wall of a rabbit is not a perfect comparison for how 
biomaterials will behave within the female pelvic floor but this 
work has allowed the variety of implantable materials to be 
narrowed down to allow only those with a safe and stable profile 
to go forward for further testing.
Another animal model that would more closely mimic the 
anatomical, physiological and biomechanical properties of the 
human female pelvic floor was required. Sheep are known to 
develop POP after multiple births58 and as such the sheep vagina 
has been identified as an appropriate model for evaluating the 
effects of different biomaterials31,59. Feola et al.31 characterised 
the differences between the host response to PPL mesh when 
implanted in the vagina versus the abdominal wall in sheep. 
The authors found that vaginally placed mesh explants had 
double the contraction and greater stiffness and fibrosis in 
comparison with the same mesh implanted on the abdominal 
wall. Young et al.60 studied the vaginal mechanical properties 
of both nulliparous and multiparous ewes through the use of a 
modified POP-quantification (POP-Q) score. Multiparous ewes 
were found to have patterns of vaginal wall weakness similar to 
those of women with increasing parity, suggesting that the former 
are a representative model for POP in humans.
Mesh controversy
“Guidance for the preparation of a premarket notification 
application for a surgical mesh” was issued by the FDA in 
199961. This stated that any company proposing a new mesh 
device should include information regarding the tensile and burst 
strength (but incidentally gave no such requirement to detail 
cyclic or fatigue testing). However, at that time, little was known 
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about the mechanical properties of the pelvic floor and what 
specification would constitute a “good” mesh product.
The initial uptake of PPL mesh amongst the urogynaecology com-
munity was extremely rapid, and a situation arose whereby there 
was an explosion of new devices on the market prior to full trial 
data becoming available. Indeed, trial data were sorely lacking 
as most devices were able to come to the market via the FDA 
510(k) process, meaning that they had to prove only “substantial 
equivalence” with a previous product62. In the case of pelvic 
mesh, this was the ProteGen sling, otherwise known as the 
grandfather mesh63. This in turn was based on the Mersilene 
mesh (an interlocked polyester fibre) being used as its predicate, 
although this product was developed for hernia repair and 
had not been tested in the pelvic floor. This meant that there 
was no requirement to prove that these new products were 
safe for use in the pelvic floor. This system was changed in 2016, 
and all transvaginal mesh devices have been reclassified from 
class II (moderate-risk device) to class III (high-risk device), 
meaning that now the 510(k) process cannot be used for their 
introduction64. Mesh manufacturers now have to provide 
detailed evidence confirming the safety and efficacy of their 
product, which was a key component that was lacking in the 
introduction of these products for use within the pelvic floor. 
The FDA state that they will continue to monitor the progress of 
patients with implanted transvaginal mesh through “post market 
surveillance measures”65.
Further work has shown that the risk of mesh-related complica-
tions is highly dependent on the anatomical placement of the 
mesh in POP repair. We now know that abdominal repair is 
associated with much lower levels of complications (10% mesh 
exposure rate at 7 years66) compared with transvaginal placement 
(12% exposure rate at 3 years67 and 42% exposure rate at 
7 years68). Adverse events are lower still with mid-urethral slings 
for SUI, and tape-related complication rates are around 4% at 
5 years69. This includes mesh exposure rates of 4%70 and rates 
of erosion into the viscera of less than 1%70. It is likely that 
several interplaying factors, including a larger surface area of 
mesh being used, lead to increased erosion/exposure rates in 
POP. There is good evidence for a chronic inflammatory response 
to an implanted mesh, leading to tissue breakdown. However, 
it is not clear why this occurs in only some patients whereas 
others have a good clinical and functional outcome from the 
procedure. Certainly, we have learnt that the environment of 
the pelvic floor is vastly different from that of the abdominal 
wall and that different forces act upon it. Indeed, the vagina in 
particular is a highly mobile structure with the potential to 
undergo significant stress and strain through both sexual activity 
and childbirth. It is therefore imperative not to assume equiva-
lent performance of the same mesh implanted in different 
sites of the body, which was the main assumption made with 
PPL mesh for abdominal hernia repair being placed into the 
pelvic floor71.
In a 2017 joint consensus statement, the European Urology 
Association and the European Urogynaecological Association5 
reached the conclusion that synthetic mesh could be safely used 
in SUI surgery but that for prolapse repair its use should be 
reserved for complex cases in specialist centres. The Scottish 
government review72 concluded that synthetic mesh procedures 
should still be offered for SUI but that they showed no addi-
tional benefit for POP. A recent update from the UK National 
Institute of Clinical Excellence (NICE) has recommended that 
transvaginal mesh repair of anterior and posterior vaginal wall 
prolapse be performed only in the context of research67 but that 
synthetic mesh for SUI still be offered. All documents stressed 
the importance of informed consent with detailed explanations 
of risks to patients prior to the procedure.
Discussion
There were several issues with the introduction of synthetic mesh 
for use within the pelvic floor. The FDA 510(k) route for intro-
duction of products to market overestimated the safety of PPL 
mesh for pelvic floor repair because of their success in treating 
abdominal wall hernia repair. As such, there was no stipulation 
for long-term trials of pelvic floor mesh prior to their wide-
spread adoption and abdominal meshes were deemed suitable 
predicates. Equally, at the time, little was known regard-
ing the unique biomechanics of the pelvic floor and hence 
this was not given the adequate emphasis prior to approval 
of the pelvic floor mesh. If the behaviour of mesh had been 
predicted within the pelvic floor and new products had not been 
brought to market simply because of predicates, there may not 
have been such a rapid dissemination of products and widespread 
complications.
The introduction of any new materials for the pelvic floor 
clearly has to proceed with caution given the severity of the 
consequences of the use of vaginally inserted PPL mesh. Many 
women have been adversely affected by the placement of PPL 
mesh; as such, there is an understandable amount of scepticism 
towards the introduction of any new materials, particularly those 
of a synthetic nature. Any new materials need to demonstrate 
robust safety data in both preclinical and animal studies before 
proceeding to clinical trial and eventually to market.
It is clear that our knowledge of what constitutes an ideal 
biomaterial for use in the pelvic floor is still evolving, but new 
technologies are rapidly expanding our understanding of the 
biomechanical properties that they would have to withstand. A 
material should be strong enough to withstand dynamic disten-
sion yet not so rigid as to cause erosion through a patient’s native 
tissue. It should be biocompatible and not produce an intense 
inflammatory reaction leading to fibrosis. It must be a product 
that is acceptable to both patients and surgeons and that is fea-
sible to insert in a single operation without requiring labora-
tory manipulation. Promising new avenues are being explored 
in tissue engineering with regard to new materials and cell 
therapies for use in the pelvic floor. New products that are likely 
to come to market will have to satisfy all regulatory hurdles 
and be acceptable to patients who are rightly sceptical given 
past product failings.
Take-home messages
1. Because of aging populations, there is an increasing number 
of women with SUI or POP. This is combined with lifestyle 
(phenotypic) factors that contribute to its occurrence (age, body 
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mass index, childbirth, smoking, among others) and genetic 
factors, such as increased breakdown of collagen or increased 
levels of proteolytic enzyme (for example, Ehlers-Danlos 
syndrome).
2. Thus, tissue-based repair has been challenging (bladder neck 
suspension for SUI and tissue plication for POP) with a high 
rate of recurrence.
3. The current PPL mesh use at the mid-urethra for SUI is the 
gold standard with long-term level-one evidence and mesh 
exposure of 3%, and erosion into the viscera of less than 1%70. 
However, it is clear that complications were identified with PPL 
used for abdominal hernia repair and it was not evaluated bio-
mechanically either in the laboratory or in animal models prior 
to being introduced into clinical practice for use within the 
pelvic floor.
4. Use of mesh in POP has improved anatomic success in 
level-one prospective trials; however, rates of complications and 
reoperations for mesh are more than 10% and this is related to the 
larger surface area of the mesh which is used70.
5. Complications are much lower in surgeons/centres with 
female pelvic health training in high volume and this is the basis 
for a recent consensus statement73.
6. Cell-based therapy for SUI has failed in clinical settings 
despite success in animal models. (Animal models sustain an 
acute injury whereas patients have a chronic injury.) Biomateri-
als and cell-based therapies conceptually offer an option but are 
still being developed (costs and regulatory approvals are currently 
prohibitive) and do not solve the patient-based tissue defect to 
replace this material. There is no commercially viable alterna-
tive to large-pore, light-weight PPL in patients with recurrent 
POP, but there is ongoing work to address this at present.
7. Synthetic material is widely accepted for SUI and abdomi-
nal (laparoscopic/robotic) use in women and hernia repair in 
men but is controversial via a vaginal approach for repair of 
POP. The European Urology Association, the FDA, the Ameri-
can Urology Association, the Society of Urodynamics, Female 
Pelvic Medicine and Urogenital Reconstruction (SUFU), and the 
American Board of Obstetrics and Gynecology policy state-
ments suggest a dialogue with the patient regarding the evidence 
of risks involved and fully informed consent5.
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